It has also been proposed that MyD88 influences Ras-related cytoplasmic ERK1/2 levels, and that MyD88-dependent signaling enhances the expressions of genes that could contribute to breast cancer progression and genes previously associated with poor outcomes in breast cancer patients [81]. Here, MYD88 is linked to breast carcinoma.